Ads
related to: simvastatin 80 mg not recommended dosenexlizet.com has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
A lower dose may be needed in people with kidney problems. [4] There is evidence of harm to the developing baby when taken during pregnancy [4] [5] and it should not be used by those who are breastfeeding. [4] It is in the statin class of medications and works by decreasing the manufacture of cholesterol by the liver. [4]
They recommended selective use of low-to-moderate doses statins in the same adults who have a calculated 10-year cardiovascular disease event risk of 7.5–10% or greater. [22] In people over the age of 70, statins decrease the risk of cardiovascular disease but only in those with a history of heavy cholesterol blockage in their arteries. [24]
If the maximum dose of statin cannot achieve the patient's goal, combination with ezetimibe is recommended. [17] An image of rosuvastatin tablets (Crestor) Caution. Atorvastatin and simvastatin are metabolized by CYP450 enzymes, leading to CYP450 enzymes related potential drug interactions; Contraindications. Active liver disease; Pregnancy or ...
The median effective dose is the dose that produces a quantal effect (all or nothing) in 50% of the population that takes it (median referring to the 50% population base). [6] It is also sometimes abbreviated as the ED 50, meaning "effective dose for 50% of the population". The ED50 is commonly used as a measure of the reasonable expectancy of ...
Sitagliptin: Using male and female rats, a two-year carcinogenicity study was carried out with doses of 50, 150, and 500 mg/kg/day. The 500 mg/kg dose has exposure limits of 60 times what would be seen in the highest dose in humans. At this dose, liver adenoma/carcinoma was seen. Tumors were not seen from the smaller doses.
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.
[citation needed] Annual cost to the UK National Health Service (NHS) in 2018, for 5–40 mg rosuvastatin daily (of one person) was £24-40, compared to £10-20 for 20–80 mg simvastatin. [38] In 2013, it was the fourth-highest-selling drug in the United States, accounting for approximately $5.2 billion in sales. [39]